Carcinoid Syndrome Management Market Information, by organs affected (Small Intestine, Lungs, Rectum, Appendix, Colon, Stomach, Pancreas, Liver and others) by Treatment (Chemotherapy, Biological therapy, and Hepatic Artery Embolization Agents), by End users (Hospital, Clinics, Cancer institute and treatment centers) Forecast to 2030

Synopsis of Carcinoid Syndrome Management Market:

Market Scenario:

The carcinoid syndrome management market is expected to reach USD 4,873.9 Million by 2030 at 10.3% CAGR during the forecast period 2022-2030.Carcinoid syndrome comprises of signs and symptoms including flushing of the face, debilitating diarrhea, asthma caused due to vasoconstriction, intestinal bleeding, fast heartbeat, shortness of breath, sweating, unexplained weight gain etc. which are settled secondary to carcinoid tumor. The management or treatment of carcinoid syndrome often requires palliative and supportive care. Management of carcinoid syndrome involves drug therapy or surgical removal of carcinoid tumor from the organ.

Increasing incidence of hormonal disorders, growing smoking habits, levels of carcinogen in highly developed countries etc. are the major driving factor, driving the growth of the market. The only factor restraining the growth of carcinoid syndrome management market is that no availability of drugs approved to manage carcinoid syndrome.

Study objectives:

• To provide detail analysis of parent market and the changing market dynamics of the industry.


• To provide detail analysis of the market structure along with estimated future growth forecast about various segments and sub-segments of the carcinoid syndrome management market.


• To provide in depth market segmentation and historical, current and projected market size in terms of value and volume with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.


• To provide country level analysis of the market with respect to the current market size and future growth prospect.


• To provide detailed analysis on recent industry trends and developments, strategies of key players and competitive landscape of the Carcinoid Syndrome Management Market.


• To track and analyze developments which are competitive in nature such as joint ventures, strategic alliances, mergers and acquisitions, new product developments along with research and developments currently taking place  in the Carcinoid Syndrome Management Market.

Figure 1           Carcinoid Syndrome Management Market by Organs Affected

Key players of Carcinoid Syndrome Management Market:

Key players profiled in the Carcinoid Syndrome Management Market are Novartis International AG (Sandoz) (Switzerland), Pharmascience Inc. (Canada), Omega Laboratories Ltd. (Canada), Teva Pharmaceutical Industries Ltd. (Israel), Mylan N.V. (USA), Ipsen Biopharmaceuticals, Inc.(US), Sirtex Medical Limited (Australia) , BTG International Ltd. (UK), Wockhardt Ltd. , and  Sun Pharmaceutical Industries Limited (India),

Segments:

The carcinoid syndrome management market is segmented on the basis of organs affected by the disease, treatment procedures and end users. Based on organs affected by the disease, the market has been segmented into small intestine, lungs, rectum, appendix, colon, stomach, pancreas, liver and others. Based on treatment type, the market has been segmented into chemotherapy, biological therapy, and hepatic artery embolization agents. Further on the basis of end users the market has been segmented as hospital, clinics, and cancer institute and treatment centers. The report for Carcinoid Syndrome Management by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.Intended Audience

• Global carcinoid syndrome management or treatment device manufacturers & suppliers


• Contract research organizations (CROs)


• Research and development (R&D) companies


• Government research laboratories


• Independent research laboratories


• Government and independent regulatory authorities


• Market research and consulting service providers


• Academic institutes and universities